Holen Sie sich die Stockscreener-App
103.08
4.80%
-5.28
Schlusskurs vom Vortag:
$108.36
Offen:
$107.67
24-Stunden-Volumen:
110.53K
Relative Volume:
0.15
Marktkapitalisierung:
$6.88B
Einnahmen:
$136.86M
Nettoeinkommen (Verlust:
$-168.69M
KGV:
-36.68
EPS:
-2.81
Netto-Cashflow:
$-113.49M
1W Leistung:
+1.50%
1M Leistung:
-8.18%
6M Leistung:
+17.48%
1J Leistung:
+76.42%
1-Tages-Spanne:
$103.04
$108.26
1-Wochen-Bereich:
$99.10
$109.02
52-Wochen-Spanne:
$45.91
$122.20
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Firmenname
Rhythm Pharmaceuticals Inc
Sektor
Branche
Telefon
857-264-4280
Adresse
222 BERKELEY STREET, BOSTON, MA
Vergleichen Sie RYTM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
103.08 | 7.23B | 136.86M | -168.69M | -113.49M | -2.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.63 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.34 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.84 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-25 | Eingeleitet | Citigroup | Buy |
| 2025-11-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-07-10 | Eingeleitet | Goldman | Buy |
| 2025-07-07 | Eingeleitet | Leerink Partners | Outperform |
| 2025-04-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-03-05 | Fortgesetzt | Stifel | Buy |
| 2025-01-02 | Eingeleitet | Jefferies | Buy |
| 2024-12-20 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-21 | Eingeleitet | Guggenheim | Buy |
| 2024-09-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-17 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-05-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-01-18 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-08-08 | Hochstufung | Goldman | Neutral → Buy |
| 2022-08-05 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-06-17 | Bestätigt | Needham | Buy |
| 2022-03-02 | Fortgesetzt | Stifel | Buy |
| 2022-02-17 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | Fortgesetzt | Goldman | Neutral |
| 2021-08-04 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-08-04 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-01-08 | Eingeleitet | Goldman | Sell |
| 2019-07-12 | Hochstufung | Stifel | Hold → Buy |
| 2019-07-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-03-13 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-09-07 | Fortgesetzt | Morgan Stanley | Overweight |
| 2018-06-25 | Bestätigt | Needham | Buy |
| 2018-06-15 | Bestätigt | Needham | Buy |
| 2017-10-30 | Eingeleitet | BofA/Merrill | Buy |
| 2017-10-30 | Eingeleitet | Needham | Buy |
Alle ansehen
Rhythm Pharmaceuticals Inc Aktie (RYTM) Neueste Nachrichten
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
What is HC Wainwright's Estimate for RYTM FY2025 Earnings? - MarketBeat
When Will Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Turn A Profit? - Yahoo Finance
Zacks Research Downgrades Rhythm Pharmaceuticals (NASDAQ:RYTM) to Strong Sell - MarketBeat
Earnings Miss: Will Rhythm Pharmaceuticals Inc stock go up in YEARTake Profit & Weekly Return Optimization Alerts - baoquankhu1.vn
Rhythm Pharmaceuticals stock price target raised to $125 from $123 at H.C. Wainwright - Investing.com Canada
Breaking Down Rhythm Pharmaceuticals: 13 Analysts Share Their Views - Benzinga
HC Wainwright & Co. Reaffirms Buy Rating for RYTM with Increased Price Target | RYTM Stock News - GuruFocus
Obesity Market on Track for Major Expansion by 2034, According to DelveInsight | Rhythm Pharmaceuticals, Boehringer Ingelheim, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical, Bukwang Pharm - Barchart.com
Rhythm Pharmaceuticals (NASDAQ:RYTM) Trading Down 5.3%Time to Sell? - MarketBeat
SG Americas Securities LLC Buys 13,369 Shares of Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Rhythm Pharmaceuticals, Inc. $RYTM Holdings Lifted by Nisa Investment Advisors LLC - MarketBeat
Death Cross: Is Rhythm Pharmaceuticals Inc currently under institutional pressureJuly 2025 Summary & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Responsive Playbooks and the RYTM Inflection - Stock Traders Daily
Investment Report: Can Rhythm Pharmaceuticals Inc expand into new markets2025 Fundamental Recap & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: A Biotech Gem with 38% Potential Upside - DirectorsTalk Interviews
What Rhythm Pharmaceuticals (RYTM)'s Strong IMCIVREE Revenue Beat Means For Shareholders - Sahm
Rhythm Pharmaceuticals stock price target raised to $130 from $120 at TD Cowen - Investing.com Canada
RYTM Stock Jumps 4% On Imcivree Revenue Growth: Firm Awaits Approval In Acquired Hypothalamic Obesity By March - Stocktwits
Needham Raises Price Target for Rhythm Pharmaceuticals (RYTM) to $148 | RYTM Stock News - GuruFocus
Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Expected to Rise, Needham & Company LLC Analyst Says - MarketBeat
Rhythm Pharmaceuticals (RYTM) Projects Strong Revenue Growth for 2025 - GuruFocus
Rhythm Pharmaceuticals announces preliminary, unaudited fourth quarter results - marketscreener.com
Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones - The Manila Times
How cyclical is Rhythm Pharmaceuticals Inc. (1RV) stock compared to rivalsJuly 2025 Reactions & High Win Rate Trade Tips - Улправда
How Rhythm Pharmaceuticals Inc. stock reacts to oil prices2025 Fundamental Recap & Community Verified Trade Alerts - ulpravda.ru
CEO Moves: Why Rhythm Pharmaceuticals Inc. (1RV) stock fits value portfolios2025 Biggest Moves & Advanced Swing Trade Entry Alerts - Улправда
Rhythm Pharmaceuticals, Inc. (RYTM): Analyst Consensus and Growth Potential Amidst a 32% Upside - DirectorsTalk Interviews
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Tops Revenue Estimates - MSN
Understanding the Setup: (RYTM) and Scalable Risk - Stock Traders Daily
Is Rhythm Pharmaceuticals Inc a good long term investmentEconomic Indicators Overview & No Fee. No Catch. Just Smart Investment Ideas - earlytimes.in
What Technical Indicators Signal for BLS E Next MonthCandlestick Trading Patterns & Identify Breakout Stocks - earlytimes.in
Rhythm Pharmaceuticals Faces Gravity: FDA Delays and Valuation Pressures Cool 2025’s Biotech Darling - FinancialContent
Rhythm Pharmaceuticals (RYTM) stock falls today as biotech weakens; FDA decision stays in focus - ts2.tech
Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Down 3.3%Should You Sell? - MarketBeat
Rhythm advances lead asset into late-stage trial in Prader-Willi syndrome - MSN
Rhythm Pharma’s Rare-Obesity Drug Keeps Growth Rolling - Finimize
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Does Rhythm Pharmaceuticals (NASDAQ:RYTM) Have A Healthy Balance Sheet? - 富途牛牛
Harbor Capital Advisors Inc. Has $3.76 Million Position in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Rhythm Pharmaceuticals (FRA:1RV) OCF Margin % : -51.90% (As of Sep. 2025) - GuruFocus
Rhythm Pharmaceuticals (FRA:1RV) EV-to-FCF : -62.60 (As of Dec. 25, 2025) - GuruFocus
Rhythm Pharmaceuticals (FRA:1RV) EV-to-OCF : -62.60 (As of Dec. 25, 2025) - GuruFocus
Why (RYTM) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
H.C. Wainwright raises Rhythm Pharmaceuticals stock price target on PWS trial data - Investing.com Canada
RYTM: HC Wainwright Raises Price Target for Rhythm Pharmaceutica - GuruFocus
Voya Investment Management LLC Has $22.38 Million Stake in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
HC Wainwright & Co. Maintains Rhythm Pharmaceuticals (RYTM) Buy Recommendation - Nasdaq
With Rhythm Pharmaceuticals Stock Surging, Have You Considered The Downside? - Trefis
What is the fair value estimate for Rhythm Pharmaceuticals Inc. (1RV) stock in 2025Earnings Growth Summary & Weekly High Return Stock Opportunities - Улправда
How Rhythm Pharmaceuticals Inc. stock performs in weak economy2025 Major Catalysts & Safe Capital Allocation Plans - Улправда
Finanzdaten der Rhythm Pharmaceuticals Inc-Aktie (RYTM)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.38%
1.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):